- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03758664
Clinical Study of ICP-192 in Solid Tumors Patients
A Phase I/IIa, Multicenter, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics of ICP-192 in Patients With Advanced Solid Malignancies
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Jin Li, PhD
- Phone Number: 22132 8621-38804518
- Email: lijin@csco.org.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Not yet recruiting
- Zhujiang Hospital of Southern Medical University
-
Contact:
- Min Wei Ding
- Phone Number: 020-62782364
- Email: DWM-2001@163.com
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Not yet recruiting
- Henan cancer hospital & Affiliated Tumor Hospital of Zhengzhou University
-
Contact:
- Fang Xin Hou
- Phone Number: 15136130286
- Email: zlyyhouxinfang1465@zzu.edu.cn
-
-
Hunan
-
Changsha, Hunan, China, 410006
- Not yet recruiting
- Hunan cancer hospital & the affiliated cancer hospital of xiangya school of medicine ,central south university
-
Contact:
- Shan Zhi Gu
- Phone Number: 0731-89762041
- Email: gushanzhi@hnszlyy.com
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215004
- Not yet recruiting
- The Second Affiliated Hospital of Soochow University
-
Contact:
- Xiang Zhi Zhuang
- Phone Number: 68282030
- Email: 13951106391@139.com
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Not yet recruiting
- The First Bethune Hospital of Jilin University
-
Contact:
- Wei Li
- Phone Number: 0431-88782291
- Email: jdyylw@163.com
-
-
Shanghai
-
Shanghai, Shanghai, China, 200120
- Recruiting
- Shanghai East Hospital
-
Contact:
- Jin Li, PhD
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Not yet recruiting
- Cancer Hospital of The University of Chinese Academy of Sciences
-
Contact:
- Er Jie Ying
- Phone Number: 88122502
- Email: jieerying01@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- An unresectable or metastatic advanced malignant solid tumor confirmed by histopathology that has failed to respond to known treatment or has recurred;Subjects who progress under standard treatment, are intolerant to standard treatment, or do not have standard treatment (dose escalation phase)
- Tissue or cell pathology confirmed unresectable, recurrent or metastatic (AJCC version 8 TNM staging IV (2017), biliary tract malignant tumor, or intolerance to first-line chemotherapy failure (twice (defined as reduction still cannot tolerate) first-line chemotherapy, neoadjuvant/progress/adjuvant chemotherapy after 6 months recurrence can be selected (dose extension stage); - At least one evaluable disease according to RECIST1.1
- FGFR2 translocation/fusion has been reported or FGFR2 translocation/fusion has been detected in central laboratory (dose extension phase);
- Age ≥18 and ≤75
- There is at least one evaluable lesion according to RECIST1.1 criteria
- ECOG strength score is 0-1 (dose escalation stage), and ECOG strength score is 0-2 (dose expansion stage).
- The expected survival time is more than 3 months
The organ function level must meet the following requirements (subject to the upper limit of normal value in the clinical trial center):
A) bone marrow: absolute count of neutrophils (ANC)≥1.5*109/L (1500/mm3), platelet ≥75*109/L, hemoglobin ≥9g/dL; B) coagulation function: international standardized ratio of prothrombin time and partial thrombin time <1.5 times the upper limit of normal value; C) liver: serum bilirubin ≤1.5 times the upper limit of normal value (tumor involvement in the liver ≤2.5 times the upper limit of normal value), aspartic aminotransferase (AST) and alanine aminotransferase (ALT)≤3 times the upper limit of normal value (AST and ALT≤5 times the upper limit of normal value in the case of liver metastasis); D) serum creatinine ≤1.5 times the upper limit of normal value, or creatinine clearance ≥70mL/min (calculated according to the Cockroft-gult formula).
- Volunteer to enroll and sign informed consent to follow the treatment protocol and visit plan.
Exclusion Criteria:
- Previous treatment with FGFR small molecule inhibitors or antibody drugs.
- Anti-cancer therapy, such as chemotherapy (except for oral fluorouracil), immunotherapy, hormonal, targeted therapy, or investigational agents within four weeks of the first dose of ICP-192, oral fluorouracil agents within two weeks of the first dose of ICP-192.
- Major surgery within 6 weeks of the first dose of ICP-192.
- Blood phosphate persistently above ULN with intervene therapy within two weeks of the first dose of ICP-192.
- Significant GI disorder(s) that could interfere with the absorption, metabolism, or excretion of ICP-192.
- Central nervous system (CNS) metastasis
- Current clinically significant cardiovascular disease including:
- Any class 3 or 4 cardiac disease such as arrhythmia, congestive heart failure or myocardial infarction defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) < 50%, Primary cardiomyopathy, clinical significant QTc prolong history or QTc>470ms (female) QTc>450ms (male)
- Known active bleeding within 2 months of screening or 6 months of bleeding history.
- According to the investigator's judgement, there are evidences of a serious or uncontrollable systemic disease (such as unstable or uncompensated respiratory, liver or kidney disease); or any unstable systemic disease (including active clinically serious infections, uncontrolled hypertension, liver and kidney or metabolic diseases)
- History of interstitial pneumonia, deep vein thrombosis, pulmonary embolism. Stroke or intracranial hemorrhage within 6 months before the first dose of ICP-192.
- History of organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Any corneal or retinal abnormalities that may increase ocular toxicity, including but not limited to:
- History of central serous retinopathy (CSR) or retinal vein occlusion (RVO) disease or has related diseases;
- Active age-related macular degeneration (AMD);
- Diabetic retinopathy with macular edema;
- Uncontrollable glaucoma;
- Keratonosus, such as Keratitis, keratoconjunctivitis, keratopathy, corneal wear, inflammation or ulceration.
- Known active infection with HBV, HCV or HIV or any uncontrolled active systemic infection
- Any toxicities must recover to ≤ Grade 1 from prior anti-cancer therapy (excluding alopecia, nausea and vomiting).
- Lactating or pregnant women, or women who will not use contraception during the study and for 180 days after the last dose of study drug if sexually active and able to bear children.
- Investigators believe that the patients are not eligible for enrollment for the other reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ICP-192
The initial dose of ICP-192 is 2 mg, QD, and dose escalation schedule may be modified based on the safety and PK from the previous dose.
Tentatively seven dose levels will be evaluated.
|
Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified "3+3" dose escalation scheme,
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events(Phase 1 dose escalation)
Time Frame: From the time a signed and dated ICF until 28 days after last dose of study drug
|
Adverse events graded by CTCAE V5.0 as a measurement of the safety and tolerability profile of ICP-192
|
From the time a signed and dated ICF until 28 days after last dose of study drug
|
Objective Response Rate(ORR)(Phase 2a dose expansion)
Time Frame: At the end of Cycle 4(each cycle is 21 days)
|
Objective response based on assessment of confirmed Complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST).
|
At the end of Cycle 4(each cycle is 21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: At the end of Cycle 1(each cycle is 21 days)
|
Single dose PK parameters include the peak plasma concentration (Cmax)
|
At the end of Cycle 1(each cycle is 21 days)
|
AUC
Time Frame: At the end of Cycle 1(each cycle is 21 days)
|
Area under the plasma concentration vs. time curve (AUC)
|
At the end of Cycle 1(each cycle is 21 days)
|
Apparent half-life for designated elimination phases (t½)
Time Frame: At the end of Cycle 1(each cycle is 21 days)
|
will be measured and calculated with noncompartmental analysis using WinNonlin
|
At the end of Cycle 1(each cycle is 21 days)
|
Food effect
Time Frame: Day 1 - 6 after single dose
|
ICP-192 concentrations in plasma and urine after dosing in fed and fasted condition
|
Day 1 - 6 after single dose
|
Objective Response Rate(ORR) (Phase 1 dose escalation)
Time Frame: At the end of Cycle 4(each cycle is 21 days)
|
Objective response based on assessment of confirmed Complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST).
|
At the end of Cycle 4(each cycle is 21 days)
|
Disease control rate(DCR)
Time Frame: At the end of Cycle 4(each cycle is 21 days)
|
DCR based on assessment of confirmed Complete response (CR), partial response (PR) or stable disease(SD) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST).
|
At the end of Cycle 4(each cycle is 21 days)
|
Duration of Objective Response (DOR)
Time Frame: At the end of Cycle 4(each cycle is 21 days)
|
Duration of objective response is time interval from the first date that criteria for complete response or partial response are met to the first date of progression of disease
|
At the end of Cycle 4(each cycle is 21 days)
|
Progression Free Survival (PFS)
Time Frame: At the end of Cycle 4(each cycle is 21 days)
|
Progression free survival is the time period from start of study medication till the disease progression or death, whichever occurs first.
|
At the end of Cycle 4(each cycle is 21 days)
|
Correlationship between FGFR aberrations with efficacy. (Phase 2a dose expansion)
Time Frame: At the end of Cycle 4(each cycle is 21 days)
|
Correlationship between FGFR mutation/refusion with ORR
|
At the end of Cycle 4(each cycle is 21 days)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ICP-CL-00301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
Clinical Trials on ICP-192
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingBladder Urothelial CancerChina
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingIntrahepatic Cholangiocarcinoma (ICC)China
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingAdvanced Solid TumorChina
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingAdvanced Solid Tumors | Cholangiocarcinoma | Urothelial CarcinomaAustralia, United States
-
PreCision Dermatology, Inc.CompletedAtopic DermatitisUnited States
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingModerate to Severe Atopic DermatitisChina
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingModerate to Severe Plaque PsoriasisChina
-
Cordis CorporationCompletedCoronary Artery Disease
-
University of MichiganMedical University of South Carolina; University of Pennsylvania; National Institute... and other collaboratorsRecruitingBrain Injuries, TraumaticUnited States, Canada